Undervalued Dividend Stocks with Growth Potential

Aug.12.2022
Undervalued Dividend Stocks with Growth Potential
Undervalued stocks with potential for strong rebound, including Altria (MO) and Pfizer (PFE). AT&T and Lockheed Martin also highlighted.

Several undervalued stocks are expected to experience a strong rebound in the coming months, including Altria.


Tobacco company Altria (ticker symbol MO)


Source: Kristi Blokhin / Shutterstock.com


Even after the trouble with Juul, the e-cigarette manufacturer, it appears that Altria (NYSE stock code: MO) is still undervalued. Over the past year, the stock has fallen by about 6%, with a forward valuation of only 9.3 times. At the same time, the stock's yield is as high as 8.1%.


Altria is increasing its focus on its non-combustible business, and its investments will be concentrated in this area over the next few years. However, the combustible portion of the business remains the driving force of cash flow. In the second quarter, its Marlboro brand cigarettes held 42.7% of the entire cigarette market.


It is important to note that Altria holds a 45% stake in Cronos (NASDAQ stock code: CRON). Federal legalization of cannabis would serve as a significant catalyst for CRON stock and benefit Altria.


Pfizer: This pharmaceutical company is not merely a one-trick pony, as Wall Street may have believed.


AT&T: $14 billion in free cash flow should provide enough flexibility for dividends and debt repayment.


Lockheed Martin Corporation (LMT) has stated that its backlog of orders worth $135 billion may increase due to the escalating geopolitical tensions.


Altria (MO) stock is currently undervalued with a yield of 8%, even after deducting regulatory factors related to JUUL.


Source: Pisit.Sj / Shutterstock.com


Generally speaking, the main reason for holding dividend stocks is to generate regular cash flow. In addition, dividend stocks are typically low beta stocks, which can help balance overall portfolio risk. However, this does not mean that dividend stocks cannot produce healthy capital gains.


Over the past decade, the Standard and Poor's 500 High Dividend Index has had an annualized price return rate of 6.95%, while the total annualized return rate has been 8.86%. It is evident that the price return has been strong.


As global markets face uncertainty related to inflation and recession, several dividend stocks have been revised and are trading at attractive valuations. These high-quality blue-chip stocks are simply a matter of time before they fill the valuation gap. In doing so, they may outperform the broader market.


By investing in the following four dividend-paying stocks, investors can position themselves for stable income and meaningful appreciation. Given the growth prospects for the underlying companies' revenue and profits, these dividend-paying stocks are worth holding for the long term.


Pfizer (PFE)


Source: photobyphm / Shutterstock.com


Pfizer (NYSE: PFE) is one of the most attractive dividend stocks to purchase due to its low beta, strong 3.2% yield, and undervaluation. Over the past 12 months, PFE's stock price has only increased by less than 1%. Its forward P/E ratio is just 7.8, indicating significant potential for growth.


One reason for Pfizer's underperformance is investors' concerns over potential revenue declines in Covid-19 vaccine sales. However, the company's growth story is not solely tied to Covid-19. Pfizer boasts a rich pipeline of drugs, and as new candidates become commercialized, they will drive sales growth.


Pfizer generated $29.9 billion in free cash flow in 2021, which has allowed them to increase investments in research and development. At the same time, the company has been active on the acquisition front in recent quarters.


The PFE stock appears poised for an upward trend. Investors may take some risks to quickly gain capital returns in the coming months.


AT&T, one of the largest telecommunications companies in the world, has recently made headlines.


As the business continues to grow and with a forward P/E ratio of 7x, there are compelling reasons for the stock to rise by 20-30% from its current level, in addition to a forward annual yield of 6.2%. This data is sourced from Lester Balajadia / Shutterstock.com.


AT&T has witnessed a continued growth in both 5G and fiber optic users. The company seems poised to benefit from its significant investments in 5G. Currently, its 5G network covers over 255 million people, and it plans to "double its fiber coverage to reach over 300,000 locations.


AT&T has used the proceeds from the split of WarnerMedia to reduce its debt. The positive free cash flow provides flexibility for further debt reduction and dividend payouts. Management anticipates this year's free cash flow to be $14 billion USD.


Lockheed Martin Corporation (LMT)


Source: Ken Wolter/Shutterstock.com


The stock price of Lockheed Martin Corporation (NYSE: LMT) has increased by 11.5% over the past six months. However, considering its forward price-to-earnings ratio of 16.1 and dividend yield of 2.6%, the stock appears to be undervalued.


The escalation of geopolitical tensions has made the defense sector attractive. As of June 26th, Lockheed Martin, with a backlog of almost $135 billion in orders, is in a favorable position to generate profits. The backlog provides cash flow visibility for the next 12 to 24 months.


Furthermore, I anticipate that the backlog of orders will increase in the coming quarters. Many European countries have failed to meet their defense spending targets. With the escalation of tension in the region, higher defense spending will benefit Lockheed Martin Corporation.


With a steady and healthy free cash flow, Lockheed's dividend is sustainable. The company reported a free cash flow of $1 billion in the second quarter of 2022, and management anticipates a free cash flow of approximately $6 billion for the year.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is intended solely for industry discussion and research purposes.


Due to limitations in our compiling abilities, the compiled article may not fully express the same meaning as the original text. Therefore, please refer to the original article for accuracy.


2FIRSTS fully aligns its statements and positions with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and international issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11
UK Vaping Products Duty to Raise £565 Million by 2030/31
UK Vaping Products Duty to Raise £565 Million by 2030/31
The UK will introduce Vaping Products Duty on all vaping liquids from October 1, 2026, with government revenue forecast to rise from £135 million in 2026/27 to £565 million by 2030/31.
Jun.18
Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
UK consumer goods group Supreme said its vaping revenue rose 15% to £148.1 million in the year to March 31, 2026, despite the UK disposable vape ban taking effect during the period, while the company identified the Vaping Products Duty due in October as the next major industry milestone.
Regulations
Jul.03 by 2Firsts Perspectives
Adani’s Mumbai Airport Duty-Free Shops Face Scrutiny Over Nicotine Pouch Sales in India
Adani’s Mumbai Airport Duty-Free Shops Face Scrutiny Over Nicotine Pouch Sales in India
An Indian investigation found that duty-free shops at Mumbai international airport operated by billionaire Gautam Adani’s business group sold nicotine pouches in breach of the law, Reuters reported, in a case that could shape how India regulates sales of new nicotine products at airport retail outlets.
Jul.08
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
One year after the UK ban on single-use disposable vapes took effect, YouGov data commissioned by Action on Smoking and Health shows that 13% of 11-17-year-old vapers and 8% of adult vapers now mainly use disposable products.
Jun.18